WALTHAM, Mass.–(BUSINESS WIRE)–Axial Biotherapeutics, a biotechnology company dedicated to building a
unique class of gut-targeted programs for neurodegenerative diseases and
neurodevelopmental disorders, today announced that the company will
participate in the following conferences in June:
-
BIO International Convention 2019 on Monday, June 3, 2019 at
3:00 p.m. ET in Philadelphia, PA-
Panel Presentation: What’s Next: The Landscape of Innovation in
2019 and Beyond - Session ID: 537703
-
Panel Presentation: What’s Next: The Landscape of Innovation in
-
CNS Targets and Translational Strategies on Wednesday, June 19,
2019 at 8:05 a.m. ET in Boston, MA-
Presentation: Harnessing the Gut-Brain Axis to Discover Novel CNS
Therapeutics
-
Presentation: Harnessing the Gut-Brain Axis to Discover Novel CNS
-
JMP Securities Life Sciences Conference on Thursday, June 20,
2019 at 11:30 a.m. ET in New York, NY
About Axial Biotherapeutics
Axial Biotherapeutics is a clinical stage biopharmaceutical company
pioneering novel science focused on the interaction between the brain
and the gut to mitigate the causes and symptoms of CNS and other
gut-derived diseases. The Company has built a pipeline of novel
small-molecules and live biotherapeutics with lead programs to address
the significant unmet patient needs associated with Parkinson’s Disease
and Autism Spectrum Disorder.
Contacts
Investors:
Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
julie.seidel@sternir.com